Contineum Therapeutics (NASDAQ:CTNM) Stock Rating Upgraded by Wall Street Zen

Contineum Therapeutics (NASDAQ:CTNM) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

Other equities analysts have also recently issued reports about the company. Robert W. Baird boosted their price target on Contineum Therapeutics from $14.00 to $20.00 and gave the stock an “outperform” rating in a report on Friday, March 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Contineum Therapeutics in a report on Monday, April 20th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Contineum Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $19.50.

Contineum Therapeutics Stock Performance

Shares of CTNM stock opened at $14.53 on Friday. The stock has a fifty day moving average price of $13.42 and a 200 day moving average price of $12.59. The stock has a market cap of $543.28 million, a PE ratio of -7.45 and a beta of 0.89. Contineum Therapeutics has a 1 year low of $3.35 and a 1 year high of $16.33.

Contineum Therapeutics (NASDAQ:CTNM) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.16. As a group, equities research analysts predict that Contineum Therapeutics will post -1.88 earnings per share for the current year.

Institutional Investors Weigh In On Contineum Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Marex Group plc purchased a new stake in shares of Contineum Therapeutics in the second quarter valued at $45,000. Qube Research & Technologies Ltd purchased a new stake in shares of Contineum Therapeutics in the second quarter valued at $43,000. Strs Ohio purchased a new stake in shares of Contineum Therapeutics in the first quarter valued at $27,000. Dimensional Fund Advisors LP purchased a new stake in shares of Contineum Therapeutics in the first quarter valued at $782,000. Finally, Cannon Global Investment Management LLC purchased a new stake in shares of Contineum Therapeutics in the first quarter valued at $170,000.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.